文献速递瓣膜病与结构性心脏病心律失常

不同Fontan术式与血栓栓塞风险的多中心回顾性队列研究

Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan Surgery.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该北美多中心回顾性队列纳入522例Fontan患者,比较房肺连接(APC)、侧隧道(LT)和心外管道(EC)三种术式的血栓栓塞风险。中位随访11.6年,EC术式独立与较低的系统性及合并血栓栓塞风险相关,抗血小板药物亦与较低合并血栓栓塞发生率相关,而抗凝治疗未见显著关联。

要点

  • EC术式较LT术式系统性血栓栓塞风险更低(HR 0.20,95%CI 0.04–0.97)。
  • 抗血小板药物与较低合并血栓栓塞风险相关(HR 0.54,95%CI 0.32–0.92)。
  • APC术式新发房性心律失常风险较其他术式高2.82倍(p<0.001)。

核心结论

  • 控制房性心律失常和血栓预防的时变效应后,心外管道Fontan术式独立与较低血栓栓塞风险相关。

研究设计与样本

  • 北美多中心回顾性队列研究,纳入522例Fontan姑息术后患者,其中APC 21.4%、LT 41.8%、EC 36.8%。

主要发现

  • 中位随访11.6年,10年和20年免于Fontan转换、移植或死亡的比例分别为94.7%和78.9%。
  • APC、LT和EC的新发房性心律失常发生率分别为4.4、1.2和1.0例/100人年。
  • APC与房性心律失常风险增高2.82倍相关(p<0.001),LT与EC间无差异(p=0.95)。
  • 共发生71例血栓栓塞事件(32例系统性、39例静脉性),占12.8%,总体年发生率为1.1%。
  • 多因素分析中,EC较LT的系统性血栓栓塞风险HR为0.20(95%CI 0.04–0.97),合并血栓栓塞风险HR为0.34(95%CI 0.13–0.91)。

关键数值与推荐

  • 抗血小板药物与较低合并血栓栓塞事件发生率相关(HR 0.54,95%CI 0.32–0.92),抗凝治疗未见显著关联(p=0.53)。

临床怎么用

  • 对于Fontan术后患者,心外管道术式可能降低血栓栓塞风险,抗血小板治疗可能获益,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thromboembolic events contribute greatly to morbidity and mortality following Fontan surgery for univentricular hearts. OBJECTIVES: This study sought to evaluate the effect of type of Fontan surgery on thromboembolic risk. METHODS: A North American multicenter retrospective cohort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (APC) (21.4%), lateral tunnel (LT) (41.8%), or extracardiac conduit (EC) (36.8%). Thromboembolic complications and new-onset atrial arrhythmia were reviewed and classified by a blinded adjudicating committee. Thromboembolic risk across surgical techniques was assessed by multivariable competing-risk survival regression. RESULTS: Over a median follow-up of 11.6 years, 10- and 20-year freedom from Fontan conversion, transplantation, or death was 94.7% and 78.9%, respectively. New-onset atrial arrhythmias occurred in 4.4, 1.2, and 1.0 cases per 100 person-years with APC, LT, and EC, respectively. APC was associated with a 2.82-fold higher risk of developing atrial arrhythmias (p < 0.001), with no difference between LT and EC (p = 0.95). A total of 71 thromboembolic events, 32 systemic and 39 venous, occurred in 12.8% of subjects, for an overall incidence of 1.1%/year. In multivariable analyses, EC was independently associated with a lower risk of systemic (hazard ratio [HR]: 0.20 vs. LT; 95% confidence interval [CI]: 0.04 to 0.97) and combined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events. A lower incidence of combined thromboembolic events was also observed with antiplatelet agents (HR: 0.54; 95% CI: 0.32 to 0.92) but not anticoagulation (p = 0.53). CONCLUSIONS: The EC Fontan was independently associated with a lower thromboembolic risk after controlling for time-varying effects of atrial arrhythmias and thromboprophylaxis.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Deshaies C, Hamilton RM, Shohoudi A, et al. Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan Surgery. J Am Coll Cardiol. 2019. PMID: 31439217. doi:10.1016/j.jacc.2019.06.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。